Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM)

Lawson DH, Gonzalez R, Weber RW, Hutchins L, Anderson CM, Williams KN, Kong S, Jacobson E, O'Day SJ. 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM). J Clin Oncol (May 20 suppl). 2008.